{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-012372","form_type":"8-K","ticker":"XFOR","cik":"0001501697","company_name":"X4 Pharmaceuticals, Inc","filed_at":"2024-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.357092+00:00","generated_at":"2026-06-04T09:48:43.877552+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"X4 Pharma reports FY2023 net loss $101.2M; cash $115.2M; PDUFA for WHIM syndrome April 30","bullets":["Net loss $19.1M Q4 and $101.2M FY2023; R&D $15.3M Q4 and $72.0M FY2023; SG&A $9.9M Q4 and $35.5M FY2023.","Cash, equivalents, restricted cash and marketable securities of $115.2M at Dec 31, 2023; runway into 2025.","FDA PDUFA target action date April 30, 2024 for mavorixafor in WHIM syndrome; launch preparations underway.","Additional Phase 2 results and global Phase 3 trial initiation for chronic neutropenia expected in 1H24.","No guidance change; projected runway excludes debt drawdowns or potential Priority Review Voucher monetization."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-012372","json":"https://secwatch.observer/filing/0001628280-24-012372.json","markdown":"https://secwatch.observer/filing/0001628280-24-012372.md","text":"https://secwatch.observer/filing/0001628280-24-012372.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024012372/0001628280-24-012372-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024012372/xfor-20240321.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T09:48:43.877552+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"33787139a7a4c4e6fb66e41aae1189ef402816a6","claim":"X4 Pharmaceuticals, Inc reported the full year ended December 31, 2023 results: net income net loss of $101.2 million.","evidence_excerpt":"X4 reported a net loss of $19.1 million and $101.2 million for the fourth quarter and full year ended December 31, 2023, respectively","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024012372/0001628280-24-012372-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2023"},{"label":"Net income","value":"net loss of $101.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"4c46ac50d63622b5f0ff8da129e894608c5adb4a","claim":"X4 Pharmaceuticals, Inc reported the fourth quarter ended December 31, 2023 results: net income net loss of $19.1 million.","evidence_excerpt":"X4 reported a net loss of $19.1 million and $101.2 million for the fourth quarter and full year ended December 31, 2023, respectively","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024012372/0001628280-24-012372-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2023"},{"label":"Net income","value":"net loss of $19.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}